Neurofibromin-2 (Merlin) (NF2)

Neurofibromin-2 (Merlin, NF2) is a cytoskeletal-associated tumor suppressor protein encoded by the NF2 gene on chromosome 22q12. Merlin belongs to the FERM domain family, structurally related to the ERM proteins (Ezrin, Radixin, Moesin), but functionally distinct due to the absence of an actin-binding motif. Merlin regulates cell proliferation, contact-dependent growth inhibition, adhesion, and junction organization in polarized tissues. It exerts its tumor suppressor activity primarily by modulating Rac and Ras signaling pathways, activating anti-mitogenic Hippo signaling, and suppressing oncogenic gene expression. Loss-of-function mutations in NF2 lead to neurofibromatosis type 2, characterized by benign nerve sheath tumors (schwannomas), meningiomas, and other tumors. Merlin is also aberrantly regulated in several sporadic cancers, including mesothelioma, glioma, and breast cancer. Despite its central role in cell cycle control and tumor suppression, there are currently no approved drugs directly targeting Merlin/NF2. Drug development efforts focus on compensating downstream pathway dysregulation, correcting protein stability, or restoring contact inhibition lost due to Merlin deficiency.

Other names

MerlinSchwannominMoesin-ezrin-radixin-like proteinNeurofibromin-2SchwannomerlinBANFSCHACNMerli-1Bilateral acoustic neurofibromatosis proteinSWNV

Restoration of Merlin function by increasing protein stability or inhibiting its degradation. Modulation of downstream pathways affected by Merlin loss: Inhibition of Ras-MAPK, PI3K-Akt, and Hippo pathway dysregulation. Suppression of oncogenic signaling induced by Merlin deficiency. Enhancement of contact inhibition and anti-proliferative cues.